Standout Papers

Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability... 1997 2026 2006 2016 569
  1. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine* (1997)
    Kenneth S. Lown, Robert R. Mayo et al. Clinical Pharmacology & Therapeutics
  2. NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial (2018)
    Stephen A. Harrison, Mary E. Rinella et al. The Lancet

Immediate Impact

6 from Science/Nature 66 standout
Sub-graph 1 of 19

Citing Papers

Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
2025 Standout
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
2024 Standout
4 intermediate papers

Works of Stephen J. Rossi being referenced

Rosuvastatin improves the FGF19 analogue NGM282-associated lipid changes in patients with non-alcoholic steatohepatitis
2018
NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
2018 Standout
and 2 more

Author Peers

Author Last Decade Papers Cites
Stephen J. Rossi 1223 833 175 671 61 2.6k
Carlos Piera 774 932 22 240 69 2.3k
Ivo Graziadei 2032 3136 80 552 97 4.7k
Pier Maria Battezzati 1964 2186 34 681 97 4.3k
Preben Olund Kirkegaard 694 1031 6 636 145 3.6k
Andrea Crosignani 2273 2428 35 752 89 3.7k
Pierre–Michel Huet 1853 1921 17 290 87 3.7k
Sandra Milić 1382 581 28 273 64 2.4k
Satheesh Nair 2496 2142 46 206 108 4.2k
Takeshi F. Andoh 341 234 21 266 69 3.7k
David Van Thiel 1270 1525 5 204 68 3.2k

All Works

Loading papers...

Rankless by CCL
2026